2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different?
10.4166/kjg.2019.73.3.132
- Author:
Ji Hoon KIM
1
Author Information
1. Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea. kjhhepar@naver.com
- Publication Type:Practice Guideline
- Keywords:
Hepatitis B, chronic;
Guideline;
Therapeutics
- MeSH:
Continental Population Groups;
Hepatitis B, Chronic;
Hepatitis, Chronic;
Humans;
Liver
- From:The Korean Journal of Gastroenterology
2019;73(3):132-140
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The clinical practice guideline for the management of chronic hepatitis B (CHB) was originally enacted in 2004 by the Korean Association for the Study of the Liver in order to provide medical practitioners with specific medical information regarding CHB to help them facilitate their understanding of the disease and treatment of the infected patients. Other than an update on the treatment of antiviral resistance in 2014, which is a partial revision, the guidelines for the treatment of chronic hepatitis B have been revised entirely three times in 2007, 2011, and 2015. Although several major international liver association have established and revised clinical practice guidelines, since the medical environment in each country is somewhat different depending on race, region, institution, and economic conditions, it is necessary to revise the Korean guidelines to that reflect our medical environment and own research results. In this review, major change and its background will be summarized about 2018 updated clinical practice guidelines for the management of CHB.
